Clinical and Translational Research in Oncology

Strategic objectives

The following institutions will be eligible for financing through the ISCIII:

  • Development and maintenance of the clinical trials platform (Phases I, II, and III).
  • To continue to be a reference unit in the analysis of susceptibility genes in the most common tumours.
  • To consolidate the platform of prognostic and predictive biomarkers of therapeutic targets in colon cancer.
  • To consolidate the CTC (circulating tumour cell) platform in breast and colon cancer, and to develop it in other tumours such as lung and prostate.
  • To continue to be a leading group within the Research Network of Cancer Centres (RTICC) of the Instituto Carlos III.

Lines of research

  • Identification of predictive response factors and new therapeutic targets in colon, breast, glioma, and prostate cancer, and design and analysis of the efficacy of new therapies in preclinical models of these tumours.
  • Pharmacogenomic study of predictive factors of response and toxicity in colon, breast, and lung cancer. Analysis of global gene expression. Study of molecular pathological, pharmacodynamic, and pharmacogenetic determinants.
  • Liquid biopsy and biomarkers: a) Biomarkers in liquid biopsy (circulating nucleic acids, circulating tumour cells, vesicles) in cancer patients. Potential use as non-invasive prognostic and predictive biomarkers; b) Mechanistic analysis of circulating nucleic acids in vesicles in the tumour environment, and their influence on tumourigenic processes.
  • Molecular mechanisms of genetic susceptibility to cancer (breast-ovarian syndrome and Lynch syndrome).
  • Microarray and microRNA platform.

 

Research lines in PATHOLOGYCAL ANATOMY

  • Digestive cancers
  • Cutaneous neoplasms in immunocompromised individuals
  • Cancer immunopathology
  • Celiac disease
  • Inflammatory bowel disease
  • Study of biomaterials in bone

Other members of the group

Publications

Projects